We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.19%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$811M
AUM Growth
+$71.2M
Cap. Flow
+$48M
Cap. Flow %
5.92%
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$18.2M
2
BDX icon
Becton Dickinson
BDX
+$16.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$14.2M
4
CELG
Celgene Corp
CELG
+$13M
5
CI icon
Cigna
CI
+$12.6M

Top Sells

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$15.2M
2
NKTR icon
Nektar Therapeutics
NKTR
+$12.5M
3
ESPR
Esperion Therapeutics
ESPR
+$10.4M
4
COR icon
Cencora
COR
+$6.72M
5
UHS icon
Universal Health Services
UHS
+$5.94M

Sector Composition

Rank Sector Weight
1 Healthcare 94.68%
2 Technology 0.23%
3 Energy 0.22%
4 Financials 0.18%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
51
Acadia Pharmaceuticals
ACAD
$5.04B
$6.07M 0.75%
270,000
-68,882
-20% -$1.91M
RIGL icon
52
Rigel Pharmaceuticals
RIGL
$764M
$5.73M 0.71%
161,777
-31,506
-16% -$1.26M
FLXN
53
DELISTED
Flexion Therapeutics, Inc.
FLXN
$5.3M 0.65%
236,686
-25,000
-10% -$610K
ALKS icon
54
Alkermes
ALKS
$8.22B
$5.26M 0.65%
90,800
+32,000
+54% +$1.87M
ADMS
55
DELISTED
Adamas Pharmaceuticals
ADMS
$5.01M 0.62%
209,644
-483,269
-70% -$15.2M
WBA
56
DELISTED
Walgreens Boots Alliance
WBA
$4.91M 0.61%
75,000
+9,300
+14% +$664K
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.86M 0.6%
255,793
– –
ONCE
58
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.5M 0.55%
67,600
-2,600
-4% -$150K
LIVN icon
59
LivaNova
LIVN
$4.19B
$4.42M 0.55%
50,000
-3,000
-6% -$256K
CHRS icon
60
Coherus Oncology
CHRS
$199M
$3.87M 0.48%
350,000
– –
ELGX
61
DELISTED
Endologix Inc
ELGX
$3.83M 0.47%
90,600
-5,000
-5% -$215K
MDCO
62
DELISTED
Medicines Co
MDCO
$3.29M 0.41%
+100,000
New +$3.12M
EPZM
63
DELISTED
Epizyme, Inc
EPZM
$3.22M 0.4%
181,291
-36,300
-17% -$613K
OMCL icon
64
Omnicell
OMCL
$1.69B
$2.54M 0.31%
58,445
– –
ACHN
65
DELISTED
Achillion Pharmaceuticals
ACHN
$2.48M 0.31%
667,800
– –
AERI
66
DELISTED
Aerie Pharmaceuticals
AERI
$2.17M 0.27%
40,000
-86,829
-68% -$4.86M
VRAY
67
DELISTED
ViewRay, Inc.
VRAY
$2.14M 0.26%
332,385
+50,000
+18% +$417K
PVLA
68
Palvella Therapeutics
PVLA
$2.23B
$2.05M 0.25%
+3,750
New +$2.32M
ZGNX
69
DELISTED
Zogenix, Inc.
ZGNX
$2M 0.25%
50,000
-1,808
-3% -$71.7K
CMRX
70
DELISTED
Chimerix, Inc.
CMRX
$1.78M 0.22%
342,000
– –
LUMO
71
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.31M 0.16%
20,116
– –
KERX
72
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.24M 0.15%
302,157
– –
VIRX
73
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.22M 0.15%
12,860
– –
DERM
74
DELISTED
Dermira, Inc.
DERM
$759K 0.09%
95,000
– –
ADVM
75
DELISTED
Adverum Biotechnologies
ADVM
$737K 0.09%
12,701
– –
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rhenman & Partners Asset Management held 102 positions worth $811M, up 9.6% from $740M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $48M of net new capital in Q1 2018, opening 7 new positions and adding to 37 existing holdings. Its largest new stake was CVS Health: 253,868 shares worth $15.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Adamas Pharmaceuticals, an estimated $15.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2018 buy was CVS Health: 253,868 shares worth $15.8M.
  • Rhenman & Partners Asset Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $14.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2018 reduction was Adamas Pharmaceuticals, cutting an estimated $15.2M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q1 2018, selling an estimated $5.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $811M portfolio in Q1 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q1 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 9.6% quarter-over-quarter to $811M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2018, filed 11 Apr 2018.